New migraine data builds on prior clinical studies in depressionHOUSTON, Aug. 07, 2023 Nexalin Technology, Inc. today provided an update on the growing body of clinical data supporting the.
QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic Expanded.
Use of a remote electrical neuromodulation device every other day helped patients significantly reduce their number of migraine days compared with a placebo device, in new research.